Microglial Lectins in Health and Neurological Diseases
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Microglia are the innate sentinels of the central nervous system (CNS) and are responsible for the homeostasis and immune defense of the CNS. Under the influence of the local environment and cell-cell interaction, microglia exhibit a multidimensional and context-dependent phenotypes that can be cytotoxic and neuroprotective. Recent studies suggest that microglia express multitudinous types of lectins, including galectins, Siglecs, mannose-binding lectins (MBLs) and other glycan binding proteins. Because most studies that examine lectins focus on the peripheral system, the functions of lectins have not been critically investigated in the CNS. In addition, the types of brain cells that contribute to the altered levels of lectins present in diseases are often unclear. In this review, we will discuss how galectins, Siglecs, selectins and MBLs contribute to the dynamic functions of microglia. The interacting ligands of these lectins are complex glycoconjugates, which consist of glycoproteins and glycolipids that are expressed on microglia or surrounding cells. The current understanding of the heterogeneity and functions of glycans in the brain is limited. Galectins are a group of pleotropic proteins that recognize both β-galactoside-containing glycans and non- β-galactoside-containing proteins. The function and regulation of galectins have been implicated in immunomodulation, neuroinflammation, apoptosis, phagocytosis and oxidative bursts. Most Siglecs are expressed at a low level on the plasma membrane and bind to sialic acid residues for immunosurveillance and cell-cell communication. Siglecs are classified based on their inhibitory and activatory downstream signaling properties. Inhibitory Siglecs negatively regulate microglia activation upon recognizing the intact sialic acid patterns and vice versa. MBLs are expressed upon infection in cytoplasm and can be secreted in order to recognize molecules containing terminal mannose as an innate immune defense machinery. Most importantly, multiple studies have reported dysregulation of lectins in neurological disorders. Here, we reviewed recent studies on microglial lectins and their functions in CNS health and disease, and suggest that these lectin families are novel, potent therapeutic targets for neurological diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 1×
“Microglia are the CNS counterpart of macrophages and differ from other types of glial cells in terms of their origin, morphology and functions (Kettenmann et al., 2011).”
BackgroundImmunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · cited 1×
“They are widely distributed throughout the brain and spinal cord, and constitute 5%–10% of total brain cells depending on the region (Lawson et al., 1990).”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 2×
“Recent genome-wide association studies have identified CD33 as a genetic risk factor of AD (Hollingworth et al., 2011; Naj et al., 2011).”
BackgroundNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 2×
“Recent genome-wide association studies have identified CD33 as a genetic risk factor of AD (Hollingworth et al., 2011; Naj et al., 2011).”
BackgroundMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
Siglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122 · cited 3×
“H (Macauley et al., 2014).”
BackgroundGalectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion
Thurston, T. L. M., Wandel, M. P., von Muhlinen, N., Foeglein, Á., & Randow, F. (2012) · Nature · doi:10.1038/nature10744 · Cited by 1,034
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5360-06.2007 · Cited by 874
Kim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 1×
“Accumulated evidence suggest that neurons can release α-Syn to neighboring astrocytes and microglia (Kim et al., 2013).”
BackgroundCD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570 · cited 1×
“Moreover, these CD33-immunoreactive microglia exhibit a positive correlation with Aβ aggregates and plaque burden in the brain of AD patients (Bradshaw et al., 2013; Griciuc et al., 2013).”
BackgroundMicroglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562 · cited 2×
“…of neurological diseases, including multiple sclerosis (MS; Politis et al., 2012), ischemic stroke (Patel et al., 2013), Alzheimer’s disease (AD; Fuhrmann et al., 2010), Parkinson’s disease (PD; Subramaniam and Federoff, 2017), amyotrophic lateral sclerosis (ALS; Brites and Vaz, 2014),…”
BackgroundFischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
C-type lectins in immunity: recent developments
Dambuza, I. M., & Brown, G. D. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.12.002 · Cited by 482
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Thored, P., Heldmann, U., Gomes‐Leal, W., Gisler, R., Darsalia, V., Taneera, J., Nygren, J. M., Jacobsen, S. W., Ekdahl, C. T., Kokaia, Z., et al. (2009) · Glia · doi:10.1002/glia.20810 · Cited by 378 · cited 1×
“Similar to galectin-8 (Thurston et al., 2012), galectin-3 may serve as a cellular danger receptor that senses detrimental conditions FIGURE 3 | Galectin-3 is a sensor of ruptured intracellular vesicles.”
BackgroundBurguillos, M. A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quintanilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M. J., Osman, A. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.012 · Cited by 365 · cited 2×
“For instance, microglia generally do not express galectin-3, but its expression can be up-regulated by inflammatory mediators (Burguillos et al., 2015).”
BackgroundFreeman, D., Cedillos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage, A. M., Sudholt, S., Rana, A., O'Connor, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062143 · Cited by 289 · cited 2×
“Exposure of surface glycans from the ruptured vesicular membranes to the cytoplasm recruits galectin-3, which forms galectin-3 puncta (Freeman et al., 2013; Flavin et al., 2017).”
BackgroundLalancette-Hébert, M., Swarup, V., Beaulieu, J. M., Bohacek, I., Abdelhamid, E., Weng, Y. C., Sato, S., & Kriz, J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1498-12.2012 · Cited by 251 · cited 1×
“Moreover, there is a twofold increase in IL6 in the ischemic brains of galectin-3-depleted mice (Lalancette-Hébert et al., 2012).”
BackgroundIncreased PK11195 PET binding in the cortex of patients with MS correlates with disability
Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P. M., Reynolds, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635645 · Cited by 176 · cited 2×
“In this context, microglia are believed to play exacerbating roles in the inflammatory response of neurological diseases, including multiple sclerosis (MS; Politis et al., 2012), ischemic stroke (Patel et al.”
BackgroundGalectin-3 drives oligodendrocyte differentiation to control myelin integrity and function
Pasquini, L. A., Millet, V, Hoyos, H. C., Giannoni, J. P., Croci, D. O., Marder, M., Liu, F. T., Rabinovich, G. A., & Pasquini, J. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.40 · Cited by 152 · cited 2×
“For instance, galectin-3 is expressed virtually on activated microglia in various neurological disorders in vivo, while it is expressed in various cell lines derived from brain glial cells in vitro (Pasquini et al., 2011).”
BackgroundNerve growth factor promotes survival of new neurons in the adult hippocampus
Frielingsdorf, H., Simpson, D. R., Thal, L. J., & Pizzo, D. P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.015 · Cited by 151 · cited 1×
“In addition, microglia are capable of promoting neurogenesis by secreting trophic factors (such as nerve growth factor (NGF) and insulin-like growth factor 1 (IGF-1; Frielingsdorf et al., 2007; Thored et al., 2009).”
BackgroundAstrocyte reactivity after brain injury—: The role of galectins 1 and 3
Sirko, S., Irmler, M., Gascón, S., Bek, S., Schneider, S., Dimou, L., Obermann, J., De Souza Paiva, D., Poirier, F., Beckers, J., et al. (2015) · Glia · doi:10.1002/glia.22898 · Cited by 126
Gene expression profiling of scrapie-infected brain tissue
Riemer, C., Neidhold, S., Burwinkel, M., Schwarz, A., Schultz, J., Krätzschmar, J., Mönning, U., & Baier, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.124 · Cited by 108 · cited 1×
“Among the genes with altered expression, the mRNA of galectin-3 is significantly up-regulated in the medulla and pons (Riemer et al., 2004).”
BackgroundClaude, J., Linnartz-Gerlach, B., Kudin, A. P., Kunz, W. S., & Neumann, H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2211-13.2013 · Cited by 98
Sun, J. (2004) · Glycobiology · doi:10.1093/glycob/cwh107 · Cited by 56
Cited by
Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration
García-Revilla, J., Boza-Serrano, A., Espinosa-Oliva, A. M., Soto, M. S., Deierborg, T., Ruiz, R., de Pablos, R. M., Burguillos, M. A., & Venero, J. L. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05058-3 · Cited by 156
“Gal-3 bearing a single C-terminal CRD and a non-lectin collagenlike N-terminal region that mediates oligomerisation and regulatory modifications [6].”
BackgroundSiglecs in Brain Function and Neurological Disorders
Siddiqui, S. S., Matar, R., Merheb, M., Hodeify, R., Vazhappilly, C. G., Marton, J., Shamsuddin, S. A., & Al Zouabi, H. (2019) · Cells · doi:10.3390/cells8101125 · Cited by 100
Role and therapeutic implications of protein glycosylation in neuroinflammation
Rebelo, A. L., Chevalier, M. T., Russo, L., & Pandit, A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.01.004 · Cited by 50
Lee, J., Kim, S. W., & Kim, K.-T. (2022) · Cells · doi:10.3390/cells11121902 · Cited by 34
Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Dehelean, L., Sarbu, M., Petrut, A., & Zamfir, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_42 · Cited by 16
Metadata
- Authors
- Siew, J. J., & Chern, Y.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-05-14
- Volume
- 11
- Pages
- 158-158
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2804367609
- Cited by
- 58
- References
- 30
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.